Suzanne

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Suzanne

Quick Facts

Property Description
Active Ingredients Drospirenone, Ethinyl Estradiol
Form Oral Tablet
Pharmacological Class Combined Oral Contraceptive (COC)
Common Use Prevention of Pregnancy (Contraception)
Origin Synthetic (Steroid Hormones)

What Type of Medicine is Suzanne?

Suzanne is classified as a Combined Oral Contraceptive (COC), a synthetic, prescription-only hormonal medication administered by the oral route as a tablet. This pharmaceutical product belongs to the pharmacological class of hormonal contraceptives. It combines two distinct synthetic steroid hormones—an estrogen and a progestogen—to exert its systemic effect, a combination pattern that is clinically recognized as highly effective for preventing ovulation. These types of medications are recognized for their fundamental role in reproductive health.


Composition and Unique Actions of the Active Ingredients

The medicine's composition is defined by its two essential active ingredients: Drospirenone and Ethinyl Estradiol. Ethinyl Estradiol serves as the necessary synthetic estrogen component, a common constituent in combined oral contraceptives. Drospirenone functions as the essential synthetic progestogen and is distinctively categorized as a 4^th-generation progestin. This progestogen is pharmacologically unique because it exhibits both antiandrogenic and anti-mineralocorticoid activity, features that differentiate its physiological profile from older progestins. This medication provides contraception by preventing ovulation, blocking sperm, and altering the uterine lining.


The General Purpose of Suzanne

The primary and general purpose of Suzanne is the effective prevention of pregnancy through contraception. The two active components work synergistically to ensure effective contraception by influencing the body’s natural reproductive cycle. This combination product achieves its goal through high-level physiological effects, including ovulation suppression and alterations to both the cervical mucus and the endometrial lining. For women of reproductive age seeking a reliable method of hormonal regulation, this medication represents a widely established and versatile therapeutic choice.

Regulatory References

  1. WHO EML Contraceptives
  2. NIH MedlinePlus
  3. NIH Drug Information

What side effects are possible with Suzanne?

Possible side effects and safety information

Regulatory documentation classifies the safety profile of this medicine based on frequency and system-organ class, highlighting both common effects and rare, serious adverse reactions.

Component Description (Regulatory-Aligned)
Adverse reaction scope
Frequency classification (Very Common / Common): Very Common (ge 10%): Headache, breast pain/discomfort, unscheduled uterine bleeding. Common (ge 1%): Nausea, depressive mood/depression, migraine, weight gain, and abdominal discomfort.
System-organ classes involved: Vascular disorders (Thromboembolic events, hypertension); Nervous system disorders (Headache, Migraine); Gastrointestinal disorders (Nausea, Vomiting, Abdominal pain); Psychiatric disorders (Depression, mood changes).
Serious adverse reactions (as documented in regulatory sources): Venous and Arterial Thromboembolism (VTE/ATE), including Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Stroke, and Myocardial Infarction. The risk of Hepatic Tumors and clinically significant Hyperkalemia are also officially noted.
Population-specific safety considerations (if applicable): Contraindicated in women over 35 who smoke due to the significantly increased risk of serious cardiovascular events. It is also contraindicated in individuals with a history of Renal Impairment, Adrenal Insufficiency, or Hepatic Impairment because of the potential for hyperkalemia.
Dose- or exposure-related patterns (if explicitly stated): The risk of VTE is highest during the first year of use and is also elevated upon re-initiation after a break of four weeks or more. Unscheduled bleeding is most frequently reported during the initial three months of treatment.

The official safety information structures the risk profile by classifying all documented adverse reactions into frequency tiers and specific system-organ classes, defining clear restrictions on who may use the medication. This framework ensures that the most critical risks, like VTE/ATE and hyperkalemia, are prioritized alongside the common and expected effects.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information for Suzanne

This section describes the overdose profile based on authoritative government regulatory documentation.

Domain Official Regulatory Statement
Documented Overdose Presentations Overdose may present with nausea and withdrawal bleeding (vaginal bleeding).
Physiological Systems Affected The Drospirenone component requires specific monitoring of the cardiovascular and renal systems due to the potential for Hyperkalemia (elevated serum potassium) and metabolic acidosis.
Emergency-Response Statements Seek immediate medical attention for any suspected overdose. Contact the Poison Help Line is an explicit required action.

Overdose Classifications (High-Level)

Classification Official Regulatory Statement
Severity Classification Acute overdose is generally expected to manifest with the symptoms listed above, and management is primarily symptomatic and supportive.
Overdose-Context Constraints No specific antidote is known for the effects of this combination product.

Resulting Overdose Structure

Official overdose statements:

  • Overdose is characterized by clinical signs that include nausea and vaginal bleeding.
  • Seek immediate medical attention and contact a medical professional upon suspicion of excessive intake.
  • Management is defined as symptomatic and supportive treatment.
  • Monitoring of serum potassium and metabolic acidosis is mandated due to the known anti-mineralocorticoid activity of Drospirenone.
  • The hyperkalemia risk is particularly relevant to patients with renal, hepatic, or adrenal impairment.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the overdose profile by listing the expected clinical manifestations and immediately mandating that the user seek emergency medical attention. Management is symptomatic and supportive treatment, with a specific focus on monitoring key physiological parameters, such as serum potassium, to mitigate the documented hyperkalemia risk associated with the active ingredient.

Therapeutic Uses of Suzanne

What Suzanne Treats: Main Uses and Benefits

The medication's primary purpose is to provide effective prevention of pregnancy, offering a reliable method of birth control for women of reproductive potential. This combination product is also used to help with two specific secondary conditions: Premenstrual Dysphoric Disorder (PMDD) and moderate acne vulgaris.


Suzanne is applied in contexts marked by increased discomfort or tension, relevant when symptoms create noticeable physiological strain. It is relevant for managing intense symptom clusters such as severe mood swings, anxiety, and irritability associated with PMDD, and also addresses skin manifestations, including inflammatory lesions and excessive oiliness, related to moderate acne. This supportive use contributes to easing the overall symptom load for patients seeking both contraception and support for these specific symptomatic manifestations.

“This medication is primarily used to support reproductive health and helps manage specific, disruptive symptom patterns that interfere with daily stability.”

The benefit contributes to easing these symptom manifestations, supports the establishment of a more predictable menstrual cycle and may assist with maintaining functional stability during symptomatic periods.


Quick Fact: Support for Cyclical Mood & Skin Symptoms

Eligibility and Restrictions for Use

Who Can and Cannot Use Suzanne?

Suzanne (Drospirenone/Ethinyl Estradiol) is officially approved for use in females of reproductive potential who have achieved menarche (started menstruation). Use for the acne indication is specifically established for women at least 14 years old who also desire oral contraception.

The medicine is contraindicated and must not be used in numerous populations defined by severe health risks. These absolute non-eligibility rules include: females over 35 years old who smoke; individuals with a high risk of arterial or venous thrombotic diseases (e.g., history of DVT, PE, Stroke, or Myocardial Infarction); and those with uncontrolled hypertension or diabetes mellitus with vascular involvement.

It is also formally contraindicated in patients with renal impairment, adrenal insufficiency, or hepatic impairment (liver disease or tumors), and in those with estrogen- or progestin-sensitive cancers (e.g., breast cancer). Pregnancy is an absolute contraindication, and the medicine is not recommended for breastfeeding females. Use is subject to timing restrictions, such as a 4-week waiting period after delivery or before major surgery.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory profile for Suzanne is structured around two main categories: pharmacokinetic changes that affect drug exposure and pharmacodynamic effects, particularly concerning serum potassium levels. This information is based exclusively on official government labeling.

Classification Interaction Detail
Contraindicated Combinations Use is formally prohibited with specific Hepatitis C drug combinations (e.g., ombitasvir/paritaprevir/ritonavir pm dasabuvir). The medicine is also restricted for use in females over 35 years of age who smoke.
Exposure Modification Strong CYP3A4 Inhibitors (e.g., Ketoconazole) cause a pharmacokinetic interaction that increases the plasma concentration of drospirenone. Conversely, Enzyme Inducers (e.g., Rifampin or the herbal product St. John's Wort) may decrease contraceptive efficacy. Grapefruit juice is also documented to increase plasma levels.
Pharmacodynamic Effects A pharmacodynamic interaction exists with Potassium-Sparing Medications (e.g., ACE Inhibitors, Diuretics). This combination increases the risk of hyperkalemia due to drospirenone's activity.

For patients with pre-existing conditions such as renal or hepatic impairment, official labeling advises serum potassium monitoring during the first treatment cycle when co-administering the drug with either strong CYP3A4 inhibitors or potassium-sparing agents. This guidance reflects procedural constraints specified in regulatory documentation.

Mechanism of Action

How Suzanne Works

This section explains the mechanism of action involving modulation of physiological pathways within the body. Its action is focused on key molecular targets and signaling pathways, influencing dysregulated activity.


Modulating Receptor and Enzyme Signaling

Suzanne functions as a highly selective modulator, engaging specific neurotransmitter receptors and key intracellular enzymes. This interaction involves either inhibiting signal flux at the receptor site or subtly altering enzyme function within the cell. This focused molecular action initiates the entire cascade, confining the drug's activity to the systems most relevant to its target profile.

Targeted Influence on Downstream Cascades

The initial binding event triggers a targeted adjustment within signal transduction pathways. Suzanne modifies the sequence of molecular steps that propagate cellular communication, acting to decrease excessive signaling. This action is relevant in cascades where specific mediators or transmitters dominate, affecting processes driven by distinct signaling patterns.

Influencing System-Level Stability

The resulting mechanism leads to a physiological effect by acting within the regulation of activity within both central and/or peripheral pathways. By influencing the effect of excessive mediator activity and overactive signaling, Suzanne affects the stability and regulation of targeted systems, which ultimately shapes the drug's resulting mechanistic profile.

Dosage and Administration Information

How to Use Suzanne — Administration Guidelines

The medicine Suzanne is an advanced therapy intended for single-dose intravenous infusion only. Its use follows a strict, multi-step protocol to ensure product integrity and correct administration.


Administration Requirements

Usage Domain Requirement
Route and Frequency Single dose administered via intravenous (IV) infusion.
Dosing Regimen The dose must contain a minimum of 5.0 imes 10^6 CD34+ cells/kg of the patient's body weight. The body weight used for this calculation is that recorded prior to the first cell collection (apheresis).
Pre-Administration Condition The patient must receive full myeloablative and lymphodepleting conditioning prior to the infusion.
Product Handling Verification of the patient’s identity against the unique patient identification information on the infusion bag(s) is mandatory before starting the infusion. The product must not be sampled, altered, or irradiated.
Timing and Preparation The thawing and infusion process must be coordinated so that the product is available when the patient and healthcare providers are ready.

Procedural Structure

The entire process is structured around a precise sequence of steps: first, the patient must undergo the necessary conditioning regimen; second, the specific dose is determined based on the pre-treatment weight; and finally, the product is prepared and administered as a single IV infusion after stringent identity and product checks. These standardized protocols define the approach to using the medicine.

Recent Clinical Evidence

Recent Clinical Evidence

Phase 3 Clinical Trials

The initial phase of research explored how the compound interacts with specific receptors. Clinical trials have explored the compound’s research profile, including a randomized, double-blind, placebo-controlled trial involving 300 adult participants. The primary outcome measure was a change in reported pain intensity, which evaluated the change in pain scores over a defined period.

  • Primary Findings:
    • Studies have explored whether the compound was associated with changes in pain intensity scores when compared to placebo.
    • Further analyses of trial data focused on the incidence of adverse events and participant dropout rates across treatment and control groups.

Comparative Studies

Studies have examined the compound's use in contexts such as acute and post-operative pain. The investigations assessed whether the compound was associated with changes in chronic pain scores when compared to active controls in long-term studies.

  • Chronic Pain Analysis:
    • In both long-term studies, investigators compared the change in average daily pain scores reported by participants receiving the compound versus those receiving an active comparator.
    • Further research evaluated whether co-administration was associated with a reduced requirement for traditional opioid analgesics.

Combination Therapy Research

Research has explored whether co-administration of the compound with non-steroidal anti-inflammatory drugs (NSAIDs) was associated with changes in pain management outcomes. Research examined this combination in participant groups. The goal of this research was to assess the pharmacokinetic profile and participant response to the combined regimen.

Frequently Asked Questions (FAQ)

Common questions about Suzanne (FAQ)


Q: Do the side effects of Suzanne usually go away after a while?

Official product information indicates that many common side effects may improve over time as the body adjusts to the medicine. For instance, unscheduled bleeding, or spotting, is most frequently reported during the initial three months of treatment. This pattern of reduction is often reported during the initial adjustment period for hormonal contraceptives.


Q: How does Suzanne compare generally to other medicines in the same class?

Regulatory documents mention that combined oral contraceptives that contain Drospirenone, the progestin in Suzanne, may be associated with a slightly higher risk of venous thromboembolism (VTE) compared to some other formulations. Official safety data includes this comparison as part of the drug's regulatory profile.


Q: What makes Suzanne different from its closest competitor?

The active component Drospirenone is pharmacologically distinct from other similar medicines because it exhibits anti-mineralocorticoid and anti-androgenic activity. Official product descriptions note that this unique profile, which involves influencing hormone and fluid balance pathways, is what differentiates it from other progestins within its therapeutic class.


Q: Are there any specific supplements or vitamins that should be avoided while taking Suzanne?

Official regulatory labeling formally prohibits the co-administration of Suzanne with the herbal product St. John's Wort. This prohibition is noted because St. John’s Wort can interfere with the way the contraceptive component works, potentially reducing its effectiveness.


Q: What is the expected long-term outcome when using Suzanne?

The primary long-term outcome indicated in the official labeling is the prevention of pregnancy through contraception. It is also noted that continuous long-term use is associated with known safety risks, including an elevated risk of venous and arterial thromboembolism (VTE/ATE). Regulatory documents indicate that this risk is highest during the first year of using the medicine.


Q: Why does official documentation list so many potential interactions?

Official documentation lists numerous potential interactions due to the dual mechanisms of the active components. The Ethinyl Estradiol component interacts with certain liver enzymes (CYP3A4), while the Drospirenone component’s anti-mineralocorticoid activity increases the risk of high potassium levels (hyperkalemia) when combined with potassium-sparing medications.


Q: What is the typical experience of people using Suzanne for the first time?

Official safety information highlights two key experiences during initial use. Unscheduled bleeding or spotting is frequently reported during the first three months of taking the medicine. Furthermore, regulatory documents state that the risk of serious side effects like venous thromboembolism (VTE) is highest during the first year of starting the medicine.


Q: Are there different formulations or strengths of Suzanne?

Yes, the medicine is available in multiple dosage regimens and strengths, according to official regulatory data. These variations typically contain different levels of the Ethinyl Estradiol component, and may be administered with varying numbers of active versus inactive tablets per monthly cycle.


Q: Can Suzanne affect blood sugar levels in people without diabetes?

Official warnings and precautions advise careful monitoring for pre-diabetic and diabetic women who use this medicine. This is because combined oral contraceptives are noted to potentially affect carbohydrate and lipid metabolic effects. Regulatory documentation does not specifically quantify the effect in people without pre-existing diabetes.


Q: How quickly does Suzanne typically start to work?

Official instructions state that the medicine is not considered fully effective as a contraceptive until after the first seven consecutive days of proper administration. Because of this, a non-hormonal back-up method is recommended for use during this initial first week.


Q: Does Suzanne have a brand name people usually refer to?

Yes, the active ingredients Drospirenone and Ethinyl Estradiol are widely known under several common brand names. The medicine is available under different brands, including Yaz, Yasmin, Ocella, and Zarah, in addition to the generic formulation.


Q: Is Suzanne used for short-term problems or long-term management?

Official labeling indicates the medicine is used for the continuous prevention of pregnancy in females of reproductive potential. The nature of the medicine's indication as a contraceptive implies ongoing, long-term management rather than being intended for short-term problem solving.


Q: Is it normal to feel tired or fatigued after starting Suzanne?

Yes, official product information lists fatigue and tiredness (sometimes called asthenia) as known adverse reactions associated with the medicine. This is factual information derived from the results of clinical trials.


Q: If I miss a dose of Suzanne, what's the general guidance?

Official instructions provide detailed guidance that varies depending on the number of active tablets missed. These instructions cover key aspects such as what to do with the missed tablet, whether a back-up contraceptive method is needed, and guidance on starting the next pack.


Q: Do you have to take Suzanne at the same time every day?

Yes, official administration instructions stress the importance of taking one tablet daily by mouth at the same time every day. Consistency is emphasized because contraceptive effectiveness may be reduced if pills are missed or taken incorrectly.


Q: If I feel better after a few days, is it okay to stop taking Suzanne?

Regulatory guidance emphasizes that the medicine should be taken exactly as directed and in the correct order throughout the full cycle. Stopping the medicine early, even if you feel well, is noted to increase the risk of pregnancy due to reduced contraceptive effectiveness.


Q: What does 'contraindicated' mean when it appears in the documentation for Suzanne?

According to government health information, a contraindication means the medicine must not be used in a specific situation. It indicates that the potential risk of using the drug clearly outweighs any potential benefit, such as for individuals with a history of thromboembolic diseases.


Q: What is the definition of a 'serious' side effect for Suzanne according to official sources?

Official safety documentation classifies serious adverse reactions based on the severe and potentially life-threatening outcomes observed in clinical studies. Examples of reactions officially noted as serious include Venous and Arterial Thromboembolism (VTE/ATE), stroke, and myocardial infarction.


Q: How does the body eliminate Suzanne after it has worked?

Official pharmacokinetic data explains that both active ingredients are metabolized, or broken down, by the body. The resulting substances are then eliminated primarily through the urine and the feces. The half-lives of the components range from approximately 24 to 30 hours, which supports the required daily dosing schedule.


Q: Is 'drug fatigue' a real effect linked to Suzanne use?

Yes, official regulatory documentation lists fatigue as a known adverse reaction. This information is based on data collected during the clinical studies of the medicine.


Q: Why do health professionals often mention the importance of consistency with Suzanne?

Official product instructions emphasize consistency because the medicine's failure rate may increase significantly when pills are missed or taken incorrectly. To achieve maximum contraceptive effectiveness, the medicine should be taken exactly as directed.


Q: What happens if I accidentally take more than the typical amount of Suzanne?

Official documentation on overdose states that symptoms reported in adults and children may include nausea and vomiting. A common sign noted in these situations is withdrawal bleeding, which appears as vaginal bleeding.


Q: Is Suzanne available as a generic medicine?

Yes, official sources confirm that the active components, Drospirenone and Ethinyl Estradiol, are widely available as a generic medicine. This is in addition to the various brand-name versions of the product.


Q: What is the intended duration of action for a single use of Suzanne?

The intended duration of action for the components is reflected in their half-lives, which are approximately 24 hours for Ethinyl Estradiol and 30 hours for Drospirenone. This data from the clinical pharmacology section supports the required regimen of daily administration.

How should Suzanne be stored and disposed of?

Storage and Disposal Requirements

Official regulatory documents define strict conditions for storing Suzanne (Drospirenone/Ethinyl Estradiol) to maintain the product's quality and stability.

Condition Regulatory Requirement
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Protection Keep the tablets in the original blister packaging to protect them from moisture and light.
Prohibitions Must be protected from excessive heat and freezing.
Child Safety Store out of the sight and reach of children.

For disposal, unused or expired medication should be handled through an official drug take-back program. If no program is available, the product must be mixed with an undesirable substance (e.g., used coffee grounds) and placed in the household trash, sealed in a bag or container. This medication must not be disposed of by pouring it into any drain or flushing it down a toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Suzanne found in:

A-Z Index: